Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)2022-07-072022-07-072020-05-21O'Bryant, S. E., Zhang, F., Silverman, W., Lee, J. H., Krinsky-McHale, S. J., Pang, D., Hall, J., & Schupf, N. (2020). Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. Alzheimer's & dementia (Amsterdam, Netherlands), 12(1), e12033. https://doi.org/10.1002/dad2.120332352-8729https://hdl.handle.net/20.500.12503/31540Introduction: We sought to determine if proteomic profiles could predict risk for incident mild cognitive impairment (MCI) and Alzheimer's disease (AD) among adults with Down syndrome (DS). Methods: In a cohort of 398 adults with DS, a total of n = 186 participants were determined to be non-demented and without MCI or AD at baseline and throughout follow-up; n = 103 had incident MCI and n = 81 had incident AD. Proteomics were conducted on banked plasma samples from a previously generated algorithm. Results: The proteomic profile was highly accurate in predicting incident MCI (area under the curve [AUC] = 0.92) and incident AD (AUC = 0.88). For MCI risk, the support vector machine (SVM)-based high/low cut-point yielded an adjusted hazard ratio (HR) = 6.46 (P < .001). For AD risk, the SVM-based high/low cut-point score yielded an adjusted HR = 8.4 (P < .001). Discussion: The current results provide support for our blood-based proteomic profile for predicting risk for MCI and AD among adults with DS.http://creativecommons.org/licenses/by-nc/4.0/mild cognitive impairmentproteomicDown SyndromeCognitive DysfunctionDementiaPlasmaArticleCopyright © 2020 The Authors.121